Nebenwirkungsmanagement unter Immuntherapie

With the implementation of immunotherapy, a completely new, broad spectrum of side effects has emerged in oncology—the immune-related adverse events (irAEs). Their management differs greatly from that of classic cytotoxic side effects and is based primarily on corticosteroids, immunomodulatory agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Princk, Marika Henriette, Pervan, Mascha, Riedl, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2023
Materias:
Leitthema
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044128/
http://dx.doi.org/10.1007/s00129-023-05067-z
_version_ 1784913298258395136
author Princk, Marika Henriette
Pervan, Mascha
Riedl, Jörg
author_facet Princk, Marika Henriette
Pervan, Mascha
Riedl, Jörg
author_sort Princk, Marika Henriette
collection PubMed
description With the implementation of immunotherapy, a completely new, broad spectrum of side effects has emerged in oncology—the immune-related adverse events (irAEs). Their management differs greatly from that of classic cytotoxic side effects and is based primarily on corticosteroids, immunomodulatory agents, and treatment interruptions. Whereas some events are low grade and reversible, others can be severe and lead to permanent disorders or even death. Therefore, early recognition and treatment in the context of interdisciplinary side effects management is critical for patients’ safety, prognosis, and quality of life.
format Online
Article
Text
id pubmed-10044128
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-100441282023-03-28 Nebenwirkungsmanagement unter Immuntherapie Princk, Marika Henriette Pervan, Mascha Riedl, Jörg Gynäkologie Leitthema With the implementation of immunotherapy, a completely new, broad spectrum of side effects has emerged in oncology—the immune-related adverse events (irAEs). Their management differs greatly from that of classic cytotoxic side effects and is based primarily on corticosteroids, immunomodulatory agents, and treatment interruptions. Whereas some events are low grade and reversible, others can be severe and lead to permanent disorders or even death. Therefore, early recognition and treatment in the context of interdisciplinary side effects management is critical for patients’ safety, prognosis, and quality of life. Springer Medizin 2023-03-28 2023 /pmc/articles/PMC10044128/ http://dx.doi.org/10.1007/s00129-023-05067-z Text en © The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Leitthema
Princk, Marika Henriette
Pervan, Mascha
Riedl, Jörg
Nebenwirkungsmanagement unter Immuntherapie
title Nebenwirkungsmanagement unter Immuntherapie
title_full Nebenwirkungsmanagement unter Immuntherapie
title_fullStr Nebenwirkungsmanagement unter Immuntherapie
title_full_unstemmed Nebenwirkungsmanagement unter Immuntherapie
title_short Nebenwirkungsmanagement unter Immuntherapie
title_sort nebenwirkungsmanagement unter immuntherapie
topic Leitthema
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044128/
http://dx.doi.org/10.1007/s00129-023-05067-z
work_keys_str_mv AT princkmarikahenriette nebenwirkungsmanagementunterimmuntherapie
AT pervanmascha nebenwirkungsmanagementunterimmuntherapie
AT riedljorg nebenwirkungsmanagementunterimmuntherapie

Ejemplares similares